ParkinsonCanadaV1, Main, Exploration, bibRecord, 000887

Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable

Identifieur interne : 000887 ( Main/Exploration ); précédent : 000886; suivant : 000888

Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable

Auteurs : Jamie Eberling [États-Unis] ; Lona Vincent [États-Unis] ; Jennifer G. Goldman ; Daniel Weintraub ; Jaime Kulisevsky ; Connie Marras ; Glenn Stebbins ; Karl Kieburtz

Source :

Journal of Parkinson's disease [ 1877-7171 ] ; 2014.

RBID : PMC:4371591

English descriptors

KwdEn :
- Clinical Trials as Topic, Cognition Disorders (diagnosis), Cognition Disorders (etiology), Cognition Disorders (therapy), Disease Progression, Humans, Neuropsychological Tests, Parkinson Disease (complications), Parkinson Disease (psychology), Quality of Life.
MESH :
- complications : Parkinson Disease.
- diagnosis : Cognition Disorders.
- etiology : Cognition Disorders.
- psychology : Parkinson Disease.
- therapy : Cognition Disorders.
- Clinical Trials as Topic, Disease Progression, Humans, Neuropsychological Tests, Quality of Life.

Abstract

Cognitive impairment is a common occurrence in Parkinson's disease (PD), although the severity and specific presentation varies across patients. Initial deficits, including mild cognitive impairment (PD-MCI), may remain stable or in many cases, may progress over variable lengths of time to Parkinson's disease dementia (PDD). As there are currently no marketed treatments for milder forms of cognitive impairment, an opportunity exists to define the path for therapeutic development in this area. In the absence of a well-defined path for the approval of therapies that target PD-MCI, pharmaceutical companies are unlikely to pursue this indication. In order to move forward and improve the quality of life for PD patients, it is imperative for the field to have consensus on the definition of PD-MCI, the best instruments to measure cognitive decline, and a strategy for future clinical trials.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371591

DOI: 10.3233/JPD-140385
PubMed: 24989876
PubMed Central: 4371591

Affiliations:

États-Unis

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable</title>
<author><name sortKey="Eberling, Jamie" sort="Eberling, Jamie" uniqKey="Eberling J" first="Jamie" last="Eberling">Jamie Eberling</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Michael J. Fox Foundation for Parkinson's Research, New York, NY</wicri:regionArea>
<wicri:noRegion>NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vincent, Lona" sort="Vincent, Lona" uniqKey="Vincent L" first="Lona" last="Vincent">Lona Vincent</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Michael J. Fox Foundation for Parkinson's Research, New York, NY</wicri:regionArea>
<wicri:noRegion>NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Goldman, Jennifer G" sort="Goldman, Jennifer G" uniqKey="Goldman J" first="Jennifer G." last="Goldman">Jennifer G. Goldman</name>
<affiliation><nlm:aff id="A2"><italic>Rush University Medical Center, Chicago, IL, USA</italic>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation><nlm:aff id="A3"><italic>University of Pennsylvania, Philadelphia, PA, USA</italic>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name>
<affiliation><nlm:aff id="A4"><italic>Sant Pau Hospital, Barcelona, Spain</italic>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
<affiliation><nlm:aff id="A5"><italic>University of Toronto, Toronto, Canada</italic>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glenn" sort="Stebbins, Glenn" uniqKey="Stebbins G" first="Glenn" last="Stebbins">Glenn Stebbins</name>
<affiliation><nlm:aff id="A2"><italic>Rush University Medical Center, Chicago, IL, USA</italic>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name>
<affiliation><nlm:aff id="A6"><italic>University of Rochester, Rochester, NY, USA</italic>
</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">24989876</idno>
<idno type="pmc">4371591</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371591</idno>
<idno type="RBID">PMC:4371591</idno>
<idno type="doi">10.3233/JPD-140385</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">000765</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000765</idno>
<idno type="wicri:Area/Pmc/Curation">000765</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000765</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000390</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000390</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000812</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000812</idno>
<idno type="wicri:Area/PubMed/Curation">000812</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000812</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000812</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000812</idno>
<idno type="wicri:Area/Ncbi/Merge">001813</idno>
<idno type="wicri:Area/Ncbi/Curation">001813</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001813</idno>
<idno type="wicri:doubleKey">1877-7171:2014:Eberling J:therapeutic:development:paths</idno>
<idno type="wicri:Area/Main/Merge">000889</idno>
<idno type="wicri:Area/Main/Curation">000887</idno>
<idno type="wicri:Area/Main/Exploration">000887</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable</title>
<author><name sortKey="Eberling, Jamie" sort="Eberling, Jamie" uniqKey="Eberling J" first="Jamie" last="Eberling">Jamie Eberling</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Michael J. Fox Foundation for Parkinson's Research, New York, NY</wicri:regionArea>
<wicri:noRegion>NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vincent, Lona" sort="Vincent, Lona" uniqKey="Vincent L" first="Lona" last="Vincent">Lona Vincent</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Michael J. Fox Foundation for Parkinson's Research, New York, NY</wicri:regionArea>
<wicri:noRegion>NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Goldman, Jennifer G" sort="Goldman, Jennifer G" uniqKey="Goldman J" first="Jennifer G." last="Goldman">Jennifer G. Goldman</name>
<affiliation><nlm:aff id="A2"><italic>Rush University Medical Center, Chicago, IL, USA</italic>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation><nlm:aff id="A3"><italic>University of Pennsylvania, Philadelphia, PA, USA</italic>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name>
<affiliation><nlm:aff id="A4"><italic>Sant Pau Hospital, Barcelona, Spain</italic>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
<affiliation><nlm:aff id="A5"><italic>University of Toronto, Toronto, Canada</italic>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glenn" sort="Stebbins, Glenn" uniqKey="Stebbins G" first="Glenn" last="Stebbins">Glenn Stebbins</name>
<affiliation><nlm:aff id="A2"><italic>Rush University Medical Center, Chicago, IL, USA</italic>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name>
<affiliation><nlm:aff id="A6"><italic>University of Rochester, Rochester, NY, USA</italic>
</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of Parkinson's disease</title>
<idno type="ISSN">1877-7171</idno>
<idno type="eISSN">1877-718X</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Cognition Disorders (diagnosis)</term>
<term>Cognition Disorders (etiology)</term>
<term>Cognition Disorders (therapy)</term>
<term>Disease Progression</term>
<term>Humans</term>
<term>Neuropsychological Tests</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (psychology)</term>
<term>Quality of Life</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Cognition Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cognition Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Cognition Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Disease Progression</term>
<term>Humans</term>
<term>Neuropsychological Tests</term>
<term>Quality of Life</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">Cognitive impairment is a common occurrence in Parkinson's disease (PD), although the severity and specific presentation varies across patients. Initial deficits, including mild cognitive impairment (PD-MCI), may remain stable or in many cases, may progress over variable lengths of time to Parkinson's disease dementia (PDD). As there are currently no marketed treatments for milder forms of cognitive impairment, an opportunity exists to define the path for therapeutic development in this area. In the absence of a well-defined path for the approval of therapies that target PD-MCI, pharmaceutical companies are unlikely to pursue this indication. In order to move forward and improve the quality of life for PD patients, it is imperative for the field to have consensus on the definition of PD-MCI, the best instruments to measure cognitive decline, and a strategy for future clinical trials.</p>
</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
</list>
<tree><noCountry><name sortKey="Goldman, Jennifer G" sort="Goldman, Jennifer G" uniqKey="Goldman J" first="Jennifer G." last="Goldman">Jennifer G. Goldman</name>
<name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name>
<name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name>
<name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
<name sortKey="Stebbins, Glenn" sort="Stebbins, Glenn" uniqKey="Stebbins G" first="Glenn" last="Stebbins">Glenn Stebbins</name>
<name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
</noCountry>
<country name="États-Unis"><noRegion><name sortKey="Eberling, Jamie" sort="Eberling, Jamie" uniqKey="Eberling J" first="Jamie" last="Eberling">Jamie Eberling</name>
</noRegion>
<name sortKey="Vincent, Lona" sort="Vincent, Lona" uniqKey="Vincent L" first="Lona" last="Vincent">Lona Vincent</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000887 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000887 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:4371591
   |texte=   Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:24989876" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable

Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.